The Role of the NIH Clinical Center in Translational and Clinical Research

报告人： John I. Gallin （ M.D., Director, Clinical Center, National Institutes of Health ， USA ）

报告时间： 2014 年 5 月 31 日星期六 下午 14:00

报告地点：生物楼一楼学术报告厅

主持人：杨胜利院士

报告人简介：

In September 2012, Christopher P. Austin, M.D., was appointed the first permanent director of the National Center for Advancing Translational Sciences (NCATS). Austin, who served as director of the NCATS Division of Pre-Clinical Innovation since the creation of the Center in December 2011, is leading NCATS in its mission to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. Austin came to NIH in 2002 from Merck, where his work focused on genome-based discovery of novel targets and drugs. He began his career at NIH as the senior advisor to the director for translational research at the National Human Genome Research Institute, where he initiated the Knockout Mouse Project and the Molecular Libraries Roadmap Initiative. Austin earned an A.B. summa cum laude in biology from Princeton University and an M.D. from Harvard Medical School. He completed clinical training in internal medicine and neurology at Massachusetts General Hospital, and a research fellowship in genetics at Harvard.

Dr. John Gallin was appointed director of the NIH Clinical Center in 1994. During his tenure, Dr. Gallin has overseen the design and construction of a new research hospital for the Clinical Center, the Mark O. Hatfield Clinical Research Center, which opened to patients in 2005; the establishment of a new curriculum for clinical research training now offered globally; and development of new information systems for biomedical translational and clinical research. His primary research interest is in a rare hereditary immune disorder, chronic granulomatous disease (CGD). His laboratory described the genetic basis for several forms of CGD and has done pioneering research that has reduced life-threatening bacterial and fungal infections in CGD patients.A New York native, Dr. Gallin attended public school in New Rochelle, New York; graduated cum laude from Amherst College; and earned an MD degree at Cornell University Medical College. After a medical internship and residency at New York University's Bellevue Hospital, he received postdoctoral training in basic and clinical research in infectious diseases at NIH from 1971 to 1974. He then went back to New York University’s Bellevue Hospital as senior chief medical resident from 1974-1975 before returning to NIH.

欢迎大家出席！

报告联系人：许国旺 （ 84379530 ）